JOSÉ LUIS
DÍEZ MARTÍN
Profesor titular de universidad
Pierre and Marie Curie University
París, FranciaPublicacions en col·laboració amb investigadors/es de Pierre and Marie Curie University (12)
2022
-
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia
Bone Marrow Transplantation, Vol. 57, Núm. 11, pp. 1657-1663
-
Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (Bone Marrow Transplantation, (2022), 57, 11, (1657-1663), 10.1038/s41409-022-01781-9)
Bone Marrow Transplantation
-
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age
American Journal of Hematology, Vol. 97, Núm. 8, pp. 1065-1074
-
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 28, Núm. 9, pp. 587.e1-587.e7
-
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation, Vol. 57, Núm. 4, pp. 562-571
-
The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML
Bone Marrow Transplantation, Vol. 57, Núm. 3, pp. 384-390
2021
-
Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation, Vol. 56, Núm. 5, pp. 1047-1055
-
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Journal of Hematology and Oncology, Vol. 14, Núm. 1
2020
-
Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 10, pp. 1915-1922
2018
-
Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide
Cancer, Vol. 124, Núm. 7, pp. 1428-1437
2017
-
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
Journal of Hematology and Oncology, Vol. 10, Núm. 1, pp. 1-11
-
Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant
Haematologica, Vol. 102, Núm. 2, pp. 401-410